QuidelOrtho (QDEL) Drops -36% in 30 Days: Dissecting the Diagnostics Pressure
Key Takeaways
- QDEL has declined -36% over the past 30 days, driven primarily by a weaker-than-expected flu season impacting respiratory diagnostics demand and disappointing 2026 guidance.
- Over the past quarter, the stock has fallen -63%, reflecting broader challenges in the diagnostics sector amid moderating infectious disease activity.
- Key factors include performance in core segments like Labs and Point-of-Care diagnostics, alongside healthcare sector trends and institutional investor sentiment.
- Post-Q4 2025 earnings, despite an earnings per share (EPS) beat, shares dropped sharply due to conservative full-year outlook.
- Macro trends such as reduced seasonal illnesses have pressured revenue expectations for QuidelOrtho's immunoassay and molecular testing products.
Understanding QuidelOrtho (QDEL) and Its Business Focus
QuidelOrtho Corporation (QDEL) centers on in vitro diagnostics, delivering testing solutions across key business segments rather than tracking a traditional index. These include Labs (clinical chemistry and immunoassay tests), Transfusion Medicine (blood typing and donor screening), Point of Care (rapid testing instruments), and Molecular Diagnostics (PCR-based syndromic testing). The company's exposure is concentrated in healthcare, specifically medical devices and diagnostics, with operations in North America, Europe, and emerging markets.
From what I see, this structure explains much of the recent price behavior: heavy reliance on seasonal respiratory illnesses for revenue makes QDEL vulnerable to milder flu seasons, while transfusion and point-of-care segments offer some diversification. Sector allocation is nearly 100% healthcare, amplifying sensitivity to diagnostic demand cycles and reimbursement trends.
QDEL Price Performance: 30 Days Compared to the Quarter
Over the last 30 days, QDEL's price fell from approximately $19.12 to $12.15, a decline of -36%. The movement was volatile and trend-driven downward, with sharp drops following earnings commentary and flu season updates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
In the past quarter, the stock dropped from around $33.20 to $12.15, marking a -63% decrease. Performance was range-bound early but accelerated lower amid negative catalysts, underperforming broader healthcare benchmarks.
Key Drivers of QDEL's 30-Day Decline
The -36% drop in QDEL over the past 30 days stemmed mainly from a moderate flu season reducing demand for respiratory diagnostics, a core revenue driver. QuidelOrtho's Labs and Point-of-Care segments, which include rapid antigen tests and immunoassays, saw pressured sales expectations as infectious disease activity waned.
Q4 2025 earnings on February 11, 2026, reported an EPS beat of $0.46 versus $0.43 expected, but 2026 guidance disappointed investors with conservative revenue projections tied to seasonal weakness. Healthcare sector performance was mixed, but diagnostics lagged amid lower illness incidence. Institutional flows showed reduced positioning by major holders like BlackRock and Vanguard, contributing to selling pressure. Market sentiment shifted negative on diagnostics cyclicality, directly impacting QDEL's valuation.
Breaking Down QDEL's Quarterly Performance
QDEL's -63% quarterly decline reflected sustained weakness in diagnostics demand, exacerbated by a milder respiratory season across Labs and Molecular segments. Broader macroeconomic conditions, including stable interest rates but softening healthcare spending growth, added headwinds.
Top exposures in transfusion medicine provided limited offset, as blood screening volumes remained steady but insufficient to counter respiratory shortfalls. Institutional outflows from healthcare-focused vehicles holding QDEL amplified the downturn. Cumulative impacts from prior guidance revisions and sector cycles in medical devices led to derating, with QDEL underperforming peers like the XLV healthcare ETF.
Tickeron’s AI Screener: A Tool I Rely On
In my own research and trading, I frequently use Tickeron’s AI Screener, an AI-powered stock and ETF discovery tool that helps filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It allows scanning thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. This identifies trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. I find it particularly useful for enhancing analysis on stocks like QDEL and uncovering hidden trends.
What to Watch Next for QDEL Investors
One thing I'm watching closely is upcoming respiratory illness seasons, as fluctuations in flu and COVID-19 cases directly affect QuidelOrtho's Labs and Point-of-Care revenues. Track healthcare sector performance, including reimbursement policies and diagnostic innovation trends. Keep an eye on major holders' positioning and fund flows into healthcare ETFs like XLV. Key catalysts include next earnings for segment breakdowns, macroeconomic shifts in inflation and growth, and competitive dynamics in molecular testing. Risks involve prolonged weak seasonality and regulatory changes in transfusion medicine.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
QDEL's RSI Indicator climbs out of oversold territory
The RSI Indicator for QDEL moved out of oversold territory on May 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In of the 43 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 75 cases where QDEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for QDEL just turned positive on April 30, 2026. Looking at past instances where QDEL's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where QDEL advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
QDEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on April 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QDEL as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QDEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for QDEL entered a downward trend on May 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.380) is normal, around the industry mean (12.607). P/E Ratio (0.000) is within average values for comparable stocks, (50.865). QDEL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.650). QDEL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.023). P/S Ratio (0.264) is also within normal values, averaging (36.374).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. QDEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QDEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of diagnostic healthcare solutions
Industry MedicalNursingServices
Advertisement